Acuitas Therapeutics

캐나다 · 생명 공학

Acuitas Therapeutics is a biotechnology company based in Vancouver, specializing in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. Founded in 2009 by Dr. Thomas Madden, Dr. Pieter Cullis, and Dr. Michael Hope, Acuitas focuses on advancing drug delivery technologies through strategic partnerships with biopharmaceutical firms. The company is recognized for its LNP technology, which has been clinically validated in approved products like ONPATTRO® and COMIRNATY®. Acuitas develops optimized LNP formulations for the intracellular delivery of nucleic acids, including siRNA, mRNA, and DNA, while minimizing toxicity. They offer comprehensive support to partners, including formulation optimization, preclinical testing, and regulatory strategy. With a strong innovation pipeline, Acuitas has synthesized over 500 novel cationic lipids, contributing to the development of diverse therapeutic applications. Their commitment to collaboration and scientific advancement positions them as a leader in the field of nucleic acid-based medicine.